Pharma BD Deal Intelligence

Kaken Pharmaceutical Co., Ltd. / KalVista Pharmaceuticals, Inc.

2025 · Licensing/Option · $24M · Complete

KalVista Pharmaceuticals, through its wholly-owned subsidiary KalVista Pharmaceuticals Ltd., entered a License, Supply and Distribution Agreement granting Kaken Pharmaceutical exclusive commercialization rights in Japan to sebetralstat, an investigational oral on-demand treatment for hereditary angioedema. KalVista receives an $11 million upfront payment within 30 days and up to approximately $13 million in additional regulatory and sales milestones, plus effective royalties in the mid-twenties percent of the Japanese NHI price.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals